These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 16091755

  • 1. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.
    Xia W, Gerard CM, Liu L, Baudson NM, Ory TL, Spector NL.
    Oncogene; 2005 Sep 15; 24(41):6213-21. PubMed ID: 16091755
    [Abstract] [Full Text] [Related]

  • 2. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
    Xia W, Bisi J, Strum J, Liu L, Carrick K, Graham KM, Treece AL, Hardwicke MA, Dush M, Liao Q, Westlund RE, Zhao S, Bacus S, Spector NL.
    Cancer Res; 2006 Feb 01; 66(3):1640-7. PubMed ID: 16452223
    [Abstract] [Full Text] [Related]

  • 3. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
    Chu I, Blackwell K, Chen S, Slingerland J.
    Cancer Res; 2005 Jan 01; 65(1):18-25. PubMed ID: 15665275
    [Abstract] [Full Text] [Related]

  • 4. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
    Chen FL, Xia W, Spector NL.
    Clin Cancer Res; 2008 Nov 01; 14(21):6730-4. PubMed ID: 18980964
    [Abstract] [Full Text] [Related]

  • 5. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.
    Spector NL, Xia W, Burris H, Hurwitz H, Dees EC, Dowlati A, O'Neil B, Overmoyer B, Marcom PK, Blackwell KL, Smith DA, Koch KM, Stead A, Mangum S, Ellis MJ, Liu L, Man AK, Bremer TM, Harris J, Bacus S.
    J Clin Oncol; 2005 Apr 10; 23(11):2502-12. PubMed ID: 15684311
    [Abstract] [Full Text] [Related]

  • 6. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
    Tevaarwerk AJ, Kolesar JM.
    Clin Ther; 2009 Apr 10; 31 Pt 2():2332-48. PubMed ID: 20110044
    [Abstract] [Full Text] [Related]

  • 7. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB, Hynes NE, Lane HA.
    Cancer Res; 2002 Jun 01; 62(11):3151-8. PubMed ID: 12036928
    [Abstract] [Full Text] [Related]

  • 8. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
    Zhou Y, Li S, Hu YP, Wang J, Hauser J, Conway AN, Vinci MA, Humphrey L, Zborowska E, Willson JK, Brattain MG.
    Cancer Res; 2006 Jan 01; 66(1):404-11. PubMed ID: 16397255
    [Abstract] [Full Text] [Related]

  • 9. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.
    Xia W, Liu LH, Ho P, Spector NL.
    Oncogene; 2004 Jan 22; 23(3):646-53. PubMed ID: 14737100
    [Abstract] [Full Text] [Related]

  • 10. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.
    Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL.
    Oncogene; 2002 Sep 12; 21(41):6255-63. PubMed ID: 12214266
    [Abstract] [Full Text] [Related]

  • 11. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
    Wang S, Huang X, Lee CK, Liu B.
    Oncogene; 2010 Jul 22; 29(29):4225-36. PubMed ID: 20498641
    [Abstract] [Full Text] [Related]

  • 12. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
    Burris HA, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S, Spector NL.
    J Clin Oncol; 2005 Aug 10; 23(23):5305-13. PubMed ID: 15955900
    [Abstract] [Full Text] [Related]

  • 13. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
    Witters LM, Witkoski A, Planas-Silva MD, Berger M, Viallet J, Lipton A.
    Oncol Rep; 2007 Feb 10; 17(2):465-9. PubMed ID: 17203189
    [Abstract] [Full Text] [Related]

  • 14. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ, Goodin S.
    Clin Ther; 2008 Aug 10; 30(8):1426-47. PubMed ID: 18803986
    [Abstract] [Full Text] [Related]

  • 15. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
    Emanuel SL, Hughes TV, Adams M, Rugg CA, Fuentes-Pesquera A, Connolly PJ, Pandey N, Moreno-Mazza S, Butler J, Borowski V, Middleton SA, Gruninger RH, Story JR, Napier C, Hollister B, Greenberger LM.
    Mol Pharmacol; 2008 Feb 10; 73(2):338-48. PubMed ID: 17975007
    [Abstract] [Full Text] [Related]

  • 16. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.
    Huang X, Gao L, Wang S, Lee CK, Ordentlich P, Liu B.
    Cancer Res; 2009 Nov 01; 69(21):8403-11. PubMed ID: 19826038
    [Abstract] [Full Text] [Related]

  • 17. Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.
    Jani JP, Finn RS, Campbell M, Coleman KG, Connell RD, Currier N, Emerson EO, Floyd E, Harriman S, Kath JC, Morris J, Moyer JD, Pustilnik LR, Rafidi K, Ralston S, Rossi AM, Steyn SJ, Wagner L, Winter SM, Bhattacharya SK.
    Cancer Res; 2007 Oct 15; 67(20):9887-93. PubMed ID: 17942920
    [Abstract] [Full Text] [Related]

  • 18. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
    Maegawa M, Takeuchi K, Funakoshi E, Kawasaki K, Nishio K, Shimizu N, Ito F.
    Mol Cancer Res; 2007 Apr 15; 5(4):393-401. PubMed ID: 17426253
    [Abstract] [Full Text] [Related]

  • 19. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
    Liu H, Zang C, Emde A, Planas-Silva MD, Rosche M, Kühnl A, Schulz CO, Elstner E, Possinger K, Eucker J.
    Eur J Pharmacol; 2008 Sep 04; 591(1-3):43-51. PubMed ID: 18588872
    [Abstract] [Full Text] [Related]

  • 20. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
    Reid A, Vidal L, Shaw H, de Bono J.
    Eur J Cancer; 2007 Feb 04; 43(3):481-9. PubMed ID: 17208435
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.